Supercritical fluid technology based large porous celecoxib-PLGA microparticles do not induce pulmonary fibrosis and sustain drug delivery and efficacy for several weeks following a single dose

Journal of Controlled Release

Volumn 168, Issue 3, 2013, Pages 239-250

  Dhanda, Devender S ^a   Tyagi, Puneet ^c   Mirvish, Sidney S ^a,b   Kompella, Uday B ^a,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Celecoxib; Lung cancer; Porous microparticles; Pulmonary delivery; Supercritical fluid

Indexed keywords

BRONCHOALVEOLAR LAVAGE FLUID; CELECOXIB; LUNG CANCER; MICRO-PARTICLES; POLY-LACTIDE-CO-GLYCOLIDE; PULMONARY DELIVERY; SUPERCRITICAL FLUID TECHNOLOGY; VASCULAR ENDOTHELIAL GROWTH FACTOR;

COLLAGEN; COPOLYMERS; DISEASES; DRUG DELIVERY; EFFLUENT TREATMENT; MAMMALS; POROUS MATERIALS; SUPERCRITICAL FLUIDS; TISSUE; TOXICITY;

BIOLOGICAL ORGANS;

BENZO[A]PYRENE; CARBOPLATIN; CELECOXIB; COLLAGEN; LACTATE DEHYDROGENASE; MACROGOL; PACLITAXEL; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FEMALE; GRANULOMA; HYPERPLASIA; LUNG FIBROSIS; LUNG LAVAGE; MOUSE; NONHUMAN; POROSITY; PRIORITY JOURNAL; SINGLE DRUG DOSE; SUPERCRITICAL FLUID TECHNOLOGY; SUSTAIN DRUG DELIVERY;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZO(A)PYRENE; BRONCHOALVEOLAR LAVAGE FLUID; CARBOPLATIN; CELL COUNT; COLLAGEN; DELAYED-ACTION PREPARATIONS; FEMALE; L-LACTATE DEHYDROGENASE; LACTIC ACID; LUNG NEOPLASMS; MICE; PACLITAXEL; PARTICLE SIZE; POLYGLYCOLIC ACID; POROSITY; PULMONARY FIBROSIS; PYRAZOLES; SULFONAMIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84877041363     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.03.027     Document Type: Article

References (66)

1. S. Sundaram, R. Trivedi, C. Durairaj, R. Ramesh, B.K. Ambati, and U.B. Kompella Targeted drug and gene delivery systems for lung cancer therapy Clin. Cancer Res. 15 2009 7299 7308
2. P. Chao, M. Deshmukh, H.L. Kutscher, D. Gao, S.S. Rajan, P. Hu, D.L. Laskin, S. Stein, and P.J. Sinko Pulmonary targeting microparticulate camptothecin delivery system: anticancer evaluation in a rat orthotopic lung cancer model Anticancer Drugs 21 2010 65 76
3. D.K. Chang, C.T. Lin, C.H. Wu, and H.C. Wu A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer PLoS One 4 2009 e4171
4. M. Nassimi, C. Schleh, H.D. Lauenstein, R. Hussein, H.G. Hoymann, W. Koch, G. Pohlmann, N. Krug, K. Sewald, S. Rittinghausen, A. Braun, and C. Muller-Goymann A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung Eur. J. Pharm. Biopharm. 75 2010 107 116
5. Y. Tabata, and Y. Ikada Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage Biomaterials 9 1988 356 362
6. Y. Tabata, and Y. Ikada Macrophage phagocytosis of biodegradable microspheres composed of l-lactic acid/glycolic acid homo- and copolymers J. Biomed. Mater. Res. 22 1988 837 858
7. J.S. Patton, and P.R. Byron Inhaling medicines: delivering drugs to the body through the lungs Nat. Rev. Drug Discov. 6 2007 67 74
8. D.A. Edwards, A. Ben-Jebria, and R. Langer Recent advances in pulmonary drug delivery using large, porous inhaled particles J. Appl. Physiol. 85 1998 379 385
9. D.A. Edwards, J. Hanes, G. Caponetti, J. Hrkach, A. Ben-Jebria, M.L. Eskew, J. Mintzes, D. Deaver, N. Lotan, and R. Langer Large porous particles for pulmonary drug delivery Science 276 1997 1868 1871
10. A. Ben-Jebria, D. Chen, M.L. Eskew, R. Vanbever, R. Langer, and D.A. Edwards Large porous particles for sustained protection from carbachol-induced bronchoconstriction in guinea pigs Pharm. Res. 16 1999 555 561
11. M.J. Kwon, J.H. Bae, J.J. Kim, K. Na, and E.S. Lee Long acting porous microparticle for pulmonary protein delivery Int. J. Pharm. 333 2007 5 9
12. Y. Yang, N. Bajaj, P. Xu, K. Ohn, M.D. Tsifansky, and Y. Yeo Development of highly porous large PLGA microparticles for pulmonary drug delivery Biomaterials 30 2009 1947 1953
13. Y.J. Oh, J. Lee, J.Y. Seo, T. Rhim, S.H. Kim, H.J. Yoon, and K.Y. Lee Preparation of budesonide-loaded porous PLGA microparticles and their therapeutic efficacy in a murine asthma model J. Control. Release 150 2011 56 62
14. A.R. Ahmed, and R. Bodmeier Preparation of preformed porous PLGA microparticles and antisense oligonucleotides loading Eur. J. Pharm. Biopharm. 71 2009 264 270
15. K. Koushik, D.S. Dhanda, N.P. Cheruvu, and U.B. Kompella Pulmonary delivery of deslorelin: large-porous PLGA particles and HPbetaCD complexes Pharm. Res. 21 2004 1119 1126
16. K. Koushik, and U.B. Kompella Preparation of large porous deslorelin-PLGA microparticles with reduced residual solvent and cellular uptake using a supercritical carbon dioxide process Pharm. Res. 21 2004 524 535
17. A.J. Alberg, and J.M. Samet Epidemiology of lung cancer Chest 123 2003 21S 49S
18. N. Usami, K. Yokoi, Y. Hasegawa, H. Taniguchi, J. Shindo, M. Yamamoto, R. Suzuki, K. Imaizumi, M. Kondo, and K. Shimokata Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial Int. J. Clin. Oncol. 15 2010 583 587
19. R.A. Soslow, A.J. Dannenberg, D. Rush, B.M. Woerner, K.N. Khan, J. Masferrer, and A.T. Koki COX-2 is expressed in human pulmonary, colonic, and mammary tumors Cancer 89 2000 2637 2645
20. H. Wolff, K. Saukkonen, S. Anttila, A. Karjalainen, H. Vainio, and A. Ristimaki Expression of cyclooxygenase-2 in human lung carcinoma Cancer Res. 58 1998 4997 5001
21. J.T. Mao, M.D. Roth, M.C. Fishbein, D.R. Aberle, Z.F. Zhang, J.Y. Rao, D.P. Tashkin, L. Goodglick, E.C. Holmes, R.B. Cameron, S.M. Dubinett, R. Elashoff, E. Szabo, and D. Elashoff Lung cancer chemoprevention with celecoxib in former smokers Cancer Prev. Res. (Phila.) 4 2011 984 993
22. S.R. Olsen Taxanes and COX-2 inhibitors: from molecular pathways to clinical practice Biomed. Pharmacother. 59 Suppl. 2 2005 S306 S310
23. T. Hida, K. Kozaki, H. Muramatsu, A. Masuda, S. Shimizu, T. Mitsudomi, T. Sugiura, M. Ogawa, and T. Takahashi Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines Clin. Cancer Res. 6 2000 2006 2011
24. G.A. Alshafie, H.M. Abou-Issa, K. Seibert, and R.E. Harris Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model Oncol. Rep. 7 2000 1377 1381
25. K.M. Leahy, R.L. Ornberg, Y. Wang, B.S. Zweifel, A.T. Koki, and J.L. Masferrer Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo Cancer Res. 62 2002 625 631
26. S.P. Ayalasomayajula, and U.B. Kompella Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model Eur. J. Pharmacol. 511 2005 191 198
27. U.B. Kompella, N. Bandi, and S.P. Ayalasomayajula Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression Invest. Ophthalmol. Vis. Sci. 44 2003 1192 1201
28. S.S. Mirvish, T. Smyrk, S. Payne, H. Tuatoo, and S.C. Chen Weak carcinogenicity of 2-hydroxyethyl carbamate in strain A mice: indication that this is not a proximal metabolite of ethyl carbamate Cancer Lett. 77 1994 1 5
29. A. Takamizawa, S. Koyama, E. Sato, T. Masubuchi, K. Kubo, M. Sekiguchi, S. Nagai, and T. Izumi Bleomycin stimulates lung fibroblasts to release neutrophil and monocyte chemotactic activity J. Immunol. 162 1999 6200 6208
30. R.J. McAnulty, and G.J. Laurent Pathogenesis of lung fibrosis and potential new therapeutic strategies Exp. Nephrol. 3 1995 96 107
31. S.O.P. toxicology, committee on biological markers Biological Markers in Pulmonary Toxicology 1989 National Academy Press Washington D.C.
32. R.F. Henderson, J.M. Benson, F.F. Hahn, C.H. Hobbs, R.K. Jones, J.L. Mauderly, R.O. McClellan, and J.A. Pickrell New approaches for the evaluation of pulmonary toxicity: bronchoalveolar lavage fluid analysis Fundam. Appl. Toxicol. 5 1985 451 458
33. C.M. Swaisgood, E.L. French, C. Noga, R.H. Simon, and V.A. Ploplis The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system Am. J. Pathol. 157 2000 177 187
34. W.T. Gunning, A. Castonguay, P.J. Goldblatt, and G.D. Stoner Strain A/J mouse lung adenoma growth patterns vary when induced by different carcinogens Toxicol. Pathol. 19 1991 168 175
35. N. Bandi, S.P. Ayalasomayajula, D.S. Dhanda, J. Iwakawa, P.W. Cheng, and U.B. Kompella Intratracheal budesonide-poly(lactide-co-glycolide) microparticles reduce oxidative stress, VEGF expression, and vascular leakage in a benzo(a)pyrene-fed mouse model J. Pharm. Pharmacol. 57 2005 851 860
36. M.M. Arnold, E.M. Gorman, L.J. Schieber, E.J. Munson, and C. Berkland NanoCipro encapsulation in monodisperse large porous PLGA microparticles J. Control. Release 121 2007 100 109
37. L. Garcia-Contreras, V. Sethuraman, M. Kazantseva, V. Godfrey, and A.J. Hickey Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig J. Antimicrob. Chemother. 58 2006 980 986
38. Y. Mo, and L.Y. Lim Preparation and in vitro anticancer activity of wheat germ agglutinin (WGA)-conjugated PLGA nanoparticles loaded with paclitaxel and isopropyl myristate J. Control. Release 107 2005 30 42
39. H. Yamamoto, Y. Kuno, S. Sugimoto, H. Takeuchi, and Y. Kawashima Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions J. Control. Release 102 2005 373 381
40. K.D. Hinds, K.M. Campbell, K.M. Holland, D.H. Lewis, C.A. Piche, and P.G. Schmidt PEGylated insulin in PLGA microparticles. In vivo and in vitro analysis J. Control. Release 104 2005 447 460
41. V. Gupta, M. Davis, L.J. Hope-Weeks, and F. Ahsan PLGA microparticles encapsulating prostaglandin E(1)-hydroxypropyl-beta-cyclodextrin (PGE (1)-HPbetaCD) complex for the treatment of pulmonary arterial hypertension (PAH) Pharm. Res. 28 2011 1733 1749
42. V. Gupta, and F. Ahsan Influence of PEI as a core modifying agent on PLGA microspheres of PGE(1), a pulmonary selective vasodilator Int. J. Pharm. 413 2011 51 62
43. I.Y. Adamson, and H. Prieditis Silica deposition in the lung during epithelial injury potentiates fibrosis and increases particle translocation to lymph nodes Exp. Lung Res. 24 1998 293 306
44. I.Y. Adamson, H. Prieditis, and R. Vincent Pulmonary toxicity of an atmospheric particulate sample is due to the soluble fraction Toxicol. Appl. Pharmacol. 157 1999 43 50
45. E. Bermudez, J.B. Mangum, B.A. Wong, B. Asgharian, P.M. Hext, D.B. Warheit, and J.I. Everitt Pulmonary responses of mice, rats, and hamsters to subchronic inhalation of ultrafine titanium dioxide particles Toxicol. Sci. 77 2004 347 357
46. J.M. Benson, I.Y. Chang, Y.S. Cheng, F.F. Hahn, C.H. Kennedy, E.B. Barr, K.R. Maples, and M.B. Snipes Particle clearance and histopathology in lungs of F344/N rats and B6C3F1 mice inhaling nickel oxide or nickel sulfate Fundam. Appl. Toxicol. 28 1995 232 244
47. G. Oberdorster Significance of particle parameters in the evaluation of exposure-dose-response relationships of inhaled particles Inhal. Toxicol. 8 1996 73 89 (Suppl.)
48. A.A. Shvedova, E.R. Kisin, R. Mercer, A.R. Murray, V.J. Johnson, A.I. Potapovich, Y.Y. Tyurina, O. Gorelik, S. Arepalli, D. Schwegler-Berry, A.F. Hubbs, J. Antonini, D.E. Evans, B.K. Ku, D. Ramsey, A. Maynard, V.E. Kagan, V. Castranova, and P. Baron Unusual inflammatory and fibrogenic pulmonary responses to single-walled carbon nanotubes in mice Am. J. Physiol. Lung Cell. Mol. Physiol. 289 2005 L698 L708
49. A. Nakatani-Okuda, H. Ueda, S. Kashiwamura, A. Sekiyama, A. Kubota, Y. Fujita, S. Adachi, Y. Tsuji, T. Tanizawa, and H. Okamura Protection against bleomycin-induced lung injury by IL-18 in mice Am. J. Physiol. Lung Cell. Mol. Physiol. 289 2005 L280 L287
50. Y.C. Huang, A. Vieira, K.L. Huang, M.K. Yeh, and C.H. Chiang Pulmonary inflammation caused by chitosan microparticles J. Biomed. Mater. Res. A 75 2005 283 287
51. S.H. Phan, and S.L. Kunkel Lung cytokine production in bleomycin-induced pulmonary fibrosis Exp. Lung Res. 18 1992 29 43
52. M. Gharaee-Kermani, M. Ullenbruch, and S.H. Phan Animal models of pulmonary fibrosis Methods Mol. Med. 117 2005 251 259
53. M. Drent, N.A. Cobben, R.F. Henderson, E.F. Wouters, and M. van Dieijen-Visser Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation Eur. Respir. J. 9 1996 1736 1742
54. R.A. Jain The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices Biomaterials 21 2000 2475 2490
55. A.C. Amrite, S.P. Ayalasomayajula, N.P. Cheruvu, and U.B. Kompella Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage Invest. Ophthalmol. Vis. Sci. 47 2006 1149 1160
56. C.J. Musante, J.D. Schroeter, J.A. Rosati, T.M. Crowder, A.J. Hickey, and T.B. Martonen Factors affecting the deposition of inhaled porous drug particles J. Pharm. Sci. 91 2002 1590 1600
57. T.M. Crowder, J.A. Rosati, J.D. Schroeter, A.J. Hickey, and T.B. Martonen Fundamental effects of particle morphology on lung delivery: predictions of Stokes' law and the particular relevance to dry powder inhaler formulation and development Pharm. Res. 19 2002 239 245
58. C. Dunbar, G. Scheuch, K. Sommerer, M. DeLong, A. Verma, and R. Batycky In vitro and in vivo dose delivery characteristics of large porous particles for inhalation Int. J. Pharm. 245 2002 179 189
59. Y. Tabata, and Y. Ikada Drug delivery systems for antitumor activation of macrophages Crit. Rev. Ther. Drug Carrier Syst. 7 1990 121 148
60. D.B. Warheit, W.J. Brock, K.P. Lee, T.R. Webb, and K.L. Reed Comparative pulmonary toxicity inhalation and instillation studies with different TiO2 particle formulations: impact of surface treatments on particle toxicity Toxicol. Sci. 88 2005 514 524
61. G.A. FitzGerald, and C. Patrono The coxibs, selective inhibitors of cyclooxygenase-2 N. Engl. J. Med. 345 2001 433 442
62. R. Yoshinaka, M.A. Shibata, J. Morimoto, N. Tanigawa, and Y. Otsuki COX-2 inhibitor celecoxib suppresses tumor growth and lung metastasis of a murine mammary cancer Anticancer Res. 26 2006 4245 4254
63. E.E. Vokes, and H. Choy Targeted therapies for stage III non-small cell lung cancer: integration in the combined modality setting Lung Cancer 41 Suppl. 1 2003 S115 S121
64. H. Choy, and L. Milas Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? J. Natl. Cancer Inst. 95 2003 1440 1452
65. R. Komaki, Z. Liao, and L. Milas Improvement strategies for molecular targeting: cyclooxygenase-2 inhibitors as radiosensitizers for non-small cell lung cancer Semin. Oncol. 31 2004 47 53
66. J.L. Masferrer, A. Koki, and K. Seibert COX-2 inhibitors. A new class of antiangiogenic agents Ann. N. Y. Acad. Sci. 889 1999 84 86